Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide
Authors:
- Lina TangLTLina Tang
- Yang YaoYYYang Yao
- Yang DongYDYang Dong
- 28 August 2011
- journal article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 7 (3) , 270-275
Abstract
Aims: The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients.Methods: A retrospective analysis was conducted of 185 osteosarcoma patients treated with the four drugs mentioned above. A total of 93 patients received the Italian therapeutic treatment (IOR‐OS/N‐5: Instituto Ortopedic Rizzoli‐Section of Osteosacorma/Neoadjuvant chemotherapy‐5) and the remaining 92 patients received the therapeutic treatment optimized by our department. We compared the efficacy and toxic side effects of these two therapies.Results: The limb salvage rates, 3‐year recurrence rates and 3‐year metastasis rates of IOR‐OS/N‐5 and our optimized treatment were 52.7 and 58.7%; 20.9 and 11.4% and 44.1 and 27.2%, respectively. The 3‐year survival rates and the 3‐year disease‐free survival rates of IOR‐OS/N‐5 and our optimized treatments were 62.4 and 78.4%; and 53.6 and 67.8%, respectively. Overall survival and disease‐free survival rates were significantly different between these two treatments (P = 0.032 and 0.024, respectively). Liver function with degree III and IV damage accounted for 35.2 and 16.6% of the total adverse reactions in the IOR‐OS/N‐5 and our optimized treatment groups, respectively. Degree III–IV neutropenia accounted for 22.6 and 40.0%, respectively, in the IOR‐OS/N‐5 and optimized treatments.Conclusion: The optimization of MTX, DDP, DOX and IFO based on Chinese patients' physiology increased the tolerance and efficacy for the treatment of osteosarcoma.Keywords
This publication has 15 references indexed in Scilit:
- Treatment of Osteosarcoma. The Scandinavian Sarcoma Group Experience2009
- The Treatment of Nonmetastatic High Grade Osteosarcoma of the Extremity: Review of the Italian Rizzoli Experience. Impact on the Future2009
- Osteosarcoma: Review of the Past, Impact on the Future. The American Experience2009
- Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcomaCurrent Therapeutic Research, 2009
- Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma GroupsJournal of Clinical Oncology, 2005
- Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, ItalyEuropean Journal of Cancer, 2005
- High Dose Ifosfamide in Combination with High Dose Methotrexate, Adriamycin and Cisplatin in the Neoadjuvant Treatment of Extremity Osteosarcoma: Preliminary Results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot StudyJournal of Chemotherapy, 2002
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapyCancer, 1982
- Recent advances in the chemotherapy of metastatic osteogenic sarcomaCancer, 1972